Neopath News Release:
Neuromedical's injunction against NeoPath denied
REDMOND, Wash., May 27 (Reuters) - Medical products company NeoPath Inc. said on Wednesday that the U.S. Southern District Court for New York denied Neuromedical Systems Inc.'s motion for a preliminary injunction in its patent infringement lawsuit against NeoPath.
Neuromedical Systems's Reponse:
Court Did Not Grant Preliminary Injunction Prior to Trial, but Concluded that NSI Made Clear Showing that Its Patents Are Valid
SUFFERN, N.Y., May 27 /PRNewswire/ -- Neuromedical Systems, Inc. (NSI) (Nasdaq: NSIX) announced today that the United States District Court for the Southern District of New York had decided not to grant a preliminary injunction prior to trial enjoining NeoPath from further manufacture and sale of its AutoPap(R) 300 QC System. The court's opinion stated that a preliminary injunction is an "extraordinary and drastic remedy" which could have severe consequences if granted, and therefore the court did not want to issue such a ruling at this juncture in the case.
In the Court's opinion, NSI made a "clear showing" that its patents are valid, however, given the contradictory testimony of each party's expert witness, the court decided not to find infringement at this initial stage, prior to trial.
The Court ordered the parties to complete discovery in the case and to appear before the Court for a pre-trial conference by the end of August.
"Based on the Court's opinion, we continue to believe that NSI has a strong case," stated Paul Sohmer, M.D., President and CEO of NSI.
SOURCE Neuromedical Systems, Inc.
CO: Neuromedical Systems, Inc.
|
